Clinical Pharmacology Adaptive Therapy Group
Professor Banerji's group aims to study re-wiring of signal transduction to understand and overcome mechanisms of drug resistance and, in addition, to understand exploit cancer evolution using pharmacological tools.
We are focused on the re-wiring of signal transduction using established cell lines to control mechanisms of drug resistance and comprehend the evolution of cancer.
Rewiring of signal transduction
This group is working on the set-up and validation of a highly sensitive antibody-based assay on the Nanostring platform which will allow quantification of 50 - 100 phosphoproteins/proteins. It plans to digest tumour tissue obtained during surgery or from biopsies and expose them to a matrix of 20 - 30 anticancer drugs before obtaining phosphoproteomic data.
It also aims to use organoids and patient-derived xenografts to take this forward. The proteomic data will be modelled with the Computational Biology and Chemogenomics Team led by Professor Bissan Al-Lazikani. The group also supports PhD students studying the re-wiring of signal transduction in colon cancer and the role of stroma in influencing signal transduction.
The group also currently works with Professor Andrea Sottoriva at the Centre for Evolution and Cancer at the ICR to look at barcoding of cancer cells and the study of evolutionary trajectories of clones under experimental conditions. It is also studying mechanisms of resistance, collateral drug sensitivity and resistance of these emergent clones.
The primary area of this group is focused on the re-wiring of signal transduction using established cell lines as well as fresh cancer cells derived and isolated from patients and then exposing them to novel anticancer drugs. Pre- and post-proteomic profiling provides insights into mechanisms of drug resistance and how to overcome this with combination therapies. The initial work was carried out using cancer cells isolated from ascites and pleural effusions; the group in now developing expertise in organoid and patient-derived xenograft tissue.
The group develops its own antibody-based proteomic platforms and collaborates with teams involved in mass spectroscopic methods, led by Jyoti Choudhary. The group generates significant amounts of data and collaborates with the ICR's Computational Biology and Chemogenomics Team led by Professor Bissan Al-Lazikani to develop and decipher the data.
The secondary focus of this lab is the study of the pharmacological effects on cancer evolution in experimental models and methods to quantify this and herd cancer cells to a vulnerable state.
Professor Banerji works with Professor Andrea Sottoriva in the Centre for Evolution and Cancer at the ICR and plans to translate these concepts in to the clinic.
Vacancies at the ICR
Working at the ICR
HR Business Partner
Summary of Role We currently have an exciting opportunity for a self-motivated and experienced HR Business Partner to join our HR Operations team. You will build strong partnerships with client departments, acting as a strategic advisor to align HR initiatives with broader business goals. In addition to leading on strategic HR matters, you will manage an HR Adviser and administrative support to ensure the delivery of a high-quality, consistent HR service across both the Professional Services and Scientific Research Divisions. Your role will involve working closely with operational teams across the ICR to provide a proactive, professional, and customer-focused generalist HR service throughout the employee lifecycle, in accordance with HR policies, procedures, and agreed service standards. Key requirements: Fully qualified Member of the Chartered Institute of Personnel and Development (CIPD), ideally at Chartered Member (MCIPD) level Demonstrated experience in handling a wide range of employee relations issues, including disciplinary and grievance procedures, absence and performance management, TUPE, redundancy, and redeployment Proficiency in using the Agresso Integrated HR/Payroll system, with the flexibility to adapt to Oracle as part of upcoming system changes (desirable) Comprehensive and current understanding of UK employment legislation and HR best practice Department/Directorate Information We know that talented, brilliant, passionate people lie at the heart of the ICR. The Human Resources Directorate provides both strategic and operational advice and support across the ICR to attract and acquire, develop, retain and empower our people to achieve their full potential. This is an exciting and transformative time for the HR Directorate as we begin to implement a new People Strategy and an ERP system to better support the ICR in achieving its mission of making the discoveries that defeat cancer.
Cloud & Infrastructure Manager
The Digital Services Directorate ensures that ICR staff have the necessary technology and specialist IT support, particularly for research. The Cloud & Infrastructure Manager will oversee the cloud and on-premises infrastructure, ensuring high availability, scalability, and security for applications and data. Implement a cloud and infrastructure strategy aligned with business goals. Manage hybrid cloud environments (combining on-premises infrastructure with cloud services). Manage and optimise cloud resources for cost and performance Manage IT infrastructure (servers, storage, networking). Manage relationships with cloud vendors and service providers. Lead and mentor a team of infrastructure engineers. Develop and implement processes for infrastructure management. Communicate effectively with technical and non-technical stakeholders. Budget management for cloud and infrastructure services Capacity planning and forecasting future needs. Automation of infrastructure tasks
Employee Story
Dr Fatemeh Ahmadi Moughari is a bioinformatician working in the Functional Genomics Team, led by Rachael Natrajan, and the Bioinformatics Team, led by Syed Haider. She joined the ICR from her home country of Iran where she completed her PhD in anti-cancer drug response at Shahid Beheshti University.
"I really enjoy the multidisciplinary atmosphere here and it’s the thing that stood out when I first joined the ICR."
Industrial partnership opportunities with this group
Opportunity: A potent, orally bioavailable clinical-stage inhibitor of MPS1 with potential as a treatment for a range of cancer types including triple negative breast cancer
Commissioner: Swen Hoelder
